GYRE
Price
$7.19
Change
+$0.01 (+0.14%)
Updated
Dec 24 closing price
Capitalization
692.64M
96 days until earnings call
Intraday BUY SELL Signals
PCVX
Price
$47.65
Change
-$0.16 (-0.33%)
Updated
Dec 24 closing price
Capitalization
6.24B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GYRE vs PCVX

Header iconGYRE vs PCVX Comparison
Open Charts GYRE vs PCVXBanner chart's image
Gyre Therapeutics
Price$7.19
Change+$0.01 (+0.14%)
Volume$65.17K
Capitalization692.64M
Vaxcyte
Price$47.65
Change-$0.16 (-0.33%)
Volume$630.67K
Capitalization6.24B
GYRE vs PCVX Comparison Chart in %
GYRE
Daily Signal:
Gain/Loss:
PCVX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GYRE vs. PCVX commentary
Dec 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and PCVX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 25, 2025
Stock price -- (GYRE: $7.19 vs. PCVX: $47.65)
Brand notoriety: GYRE and PCVX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 91% vs. PCVX: 43%
Market capitalization -- GYRE: $692.64M vs. PCVX: $6.24B
GYRE [@Biotechnology] is valued at $692.64M. PCVX’s [@Biotechnology] market capitalization is $6.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 0 FA rating(s) are green whilePCVX’s FA Score has 0 green FA rating(s).

  • GYRE’s FA Score: 0 green, 5 red.
  • PCVX’s FA Score: 0 green, 5 red.
According to our system of comparison, PCVX is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 3 TA indicator(s) are bullish while PCVX’s TA Score has 6 bullish TA indicator(s).

  • GYRE’s TA Score: 3 bullish, 6 bearish.
  • PCVX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PCVX is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а -2.97% price change this week, while PCVX (@Biotechnology) price change was +10.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

GYRE is expected to report earnings on Mar 31, 2026.

PCVX is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PCVX($6.24B) has a higher market cap than GYRE($693M). GYRE (-40.579) and PCVX (-41.791) have similar YTD gains . GYRE has higher annual earnings (EBITDA): 14.4M vs. PCVX (-686.1M). PCVX has more cash in the bank: 1.71B vs. GYRE (60M). GYRE has less debt than PCVX: GYRE (1.17M) vs PCVX (84.4M). GYRE has higher revenues than PCVX: GYRE (107M) vs PCVX (0).
GYREPCVXGYRE / PCVX
Capitalization693M6.24B11%
EBITDA14.4M-686.1M-2%
Gain YTD-40.579-41.79197%
P/E Ratio179.75N/A-
Revenue107M0-
Total Cash60M1.71B4%
Total Debt1.17M84.4M1%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
61
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
94
SMR RATING
1..100
77
PRICE GROWTH RATING
1..100
77
P/E GROWTH RATING
1..100
43
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYREPCVX
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 2 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signal:
Gain/Loss:
PCVX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYSOX101.950.32
+0.31%
Rydex S&P 500 A
ASISX27.730.08
+0.29%
Invesco Asia Pacific Equity R6
IFACX25.740.05
+0.19%
American Funds Income Fund of Amer C
FTQGX38.81N/A
N/A
Fidelity Focused Stock
FMURX30.75-0.02
-0.06%
Franklin Mutual International Value R

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+0.14%
SPRC - GYRE
38%
Loosely correlated
+0.72%
RCKT - GYRE
36%
Loosely correlated
+1.74%
PCVX - GYRE
33%
Loosely correlated
-0.33%
BEAM - GYRE
33%
Loosely correlated
+1.33%
VRDN - GYRE
33%
Poorly correlated
+0.53%
More

PCVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with TSHA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then TSHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCVX
1D Price
Change %
PCVX100%
-0.33%
TSHA - PCVX
51%
Loosely correlated
+3.50%
IDYA - PCVX
46%
Loosely correlated
+0.76%
MRNA - PCVX
46%
Loosely correlated
+1.42%
RVMD - PCVX
46%
Loosely correlated
+1.15%
BEAM - PCVX
45%
Loosely correlated
+1.33%
More